What this is
- This research compares the risks of mortality and cardiovascular events in patients with type 2 diabetes (T2D) using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs. nonusers.
- The study utilized Taiwan's National Health Insurance Research Database, analyzing data from 31,183 matched pairs of GLP-1 RA users and nonusers.
- Findings indicate that GLP-1 RA use is associated with lower risks of all-cause mortality, cardiovascular events, and liver-related mortality.
Essence
- GLP-1 RA use in T2D patients is linked to lower risks of all-cause mortality, cardiovascular events, and liver-related death compared to nonuse.
Key takeaways
- GLP-1 RA users had an all-cause mortality incidence rate of 5.67 per 1000 person-years vs. 13.06 for nonusers, indicating a significant reduction in mortality risk.
- Multivariable-adjusted analysis showed GLP-1 RA use reduced the risk of cardiovascular death by 43% (aHR 0.57) and liver-related death by 68% (aHR 0.32).
- No significant differences were found in the development of liver cirrhosis, hepatic failure, or hepatocellular carcinoma between GLP-1 RA users and nonusers.
Caveats
- The study lacks detailed data on lifestyle factors like smoking, diet, and physical activity, which could influence outcomes.
- Results may not be generalizable beyond the Taiwanese population, as the cohort primarily consists of individuals of Chinese ethnicity.
- As an observational study, it may be subject to unobserved confounding factors, suggesting the need for randomized controlled trials to confirm findings.
Simplified
Background
Nonalcoholic fatty liver disease (NAFLD) is the accumulation of hepatic fat (≧5%) without much alcohol consumption (< 20 g/day) [1]. In the past 2–3 decades, NAFLD has evolved from an obscure liver disease to the most common chronic liver disease [2]. About 25% of the adult population has NAFLD worldwide [3], and the proportion of NAFLD can be more than 50% in persons with obesity or type 2 diabetes (T2D) [3]. Patients with NAFLD have 2.2 folds increased risk of type 2 diabetes development [4]. In patients with T2D, due to insulin resistance, there is overflow of free fatty acid (FFA) to the liver; the hepatocytes also have increased de novo lipogenesis, which can be re-esterified to triglyceride and accumulated in the liver, resulting in hepatic steatosis [5]. Therefore, the global prevalence of NAFLD in patients with T2D is about 55–70% [6]. From 2009 to 2019, the prevalence of NAFLD in Taiwan increased from 4.49 million to 5.43 million. The number of deaths attributed to NAFLD also increased from 900 to 1,008. Meanwhile, the prevalence of diabetes mellitus in Taiwan increased from 1.39 million in 2009 to 1.9 million in 2019, and the number of deaths attributed to diabetes mellitus increased from 8,892 in 2009 to 11,323 in 2019 [7]. Additionally, glucotoxicity and lipotoxicity in patients with coexisting T2D and NAFLD produce a significant increase in reactive oxygen species, oxidative stress, and mitochondrial dysfunction [4]. This makes the NAFLD in patients with T2D be prone to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, liver cancers, liver-related mortality, and cardiovascular mortality [4].
In response to meal intake, intestinal L-cells produce glucagon-like peptide-1 that stimulates the pancreas to secrete insulin and decrease postprandial blood glucose [8, 9]. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved for the treatment of type 2 diabetes in 2005 [9]. Large randomized clinical trials have demonstrated that GLP-1 RA can effectively reduce blood glucose, body weight, and the risk of cardiovascular diseases [9]. Animal studies reveal that GLP-1 RAs can improve insulin sensitivity and reduce oxidative stress, hepatic steatosis, and fibrosis [10]. A randomized controlled trial in 52 people with NASH showed that liraglutide improved liver function, had a significantly 30% higher rate of NASH resolution and a 27% lower risk of progression of liver fibrosis [11]. A randomized controlled trial in 320 people with NASH showed that subcutaneous semaglutide led to a significantly higher proportion of people with NASH resolution (23–42%) than placebo, but with no statistically significant difference (10%, p = 0.48) in improvement in fibrosis stage [12]. These studies demonstrated some promising results in stopping NAS progression, but they did not further investigate the preventive effects of GLP-1 RA on cirrhosis. Moreover, there are currently no approved medications for treating NAFLD and NASH [1, 2]. There are no studies evaluating GLP-1 RA in relation to cirrhosis and liver-related mortality in patients with T2D. Patients with T2D have an increased risk of cardiovascular disease and cardiovascular mortality, which has subsequently become the leading cause of death in patients with T2D for decades [13]. Therefore, we performed the data analysis from this prospective cohort study in Taiwan to compare the risks of cardiovascular diseases, liver cirrhosis, liver-related mortality, and cardiovascular mortality between GLP-1 RA use and no-use in patients with T2D (excluding those with viral hepatitis or alcohol-related disorders).
Methods
Study population and data source
The data source of this research is the full population file of Taiwan’s National Health Insurance Research Database (NHIRD). The features of the NHIRD have been described in our previous study [14]. The diagnosis of diseases in the NHIRD is based on the International Classification of Diseases Ninth/Tenth Revision, Clinical Modification (ICD-9/10-CM). The NHIRD has links to the National Death Registry dataset for death information. All patient and health care information was encrypted before release to protect the privacy of individuals. The Research Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115-CR4) approved this study and waived informed consent from patients.
Study design and procedures
We identified patients diagnosed with type 2 diabetes from the National Health Insurance Database between January 1, 2008, and December 31, 2018, who received follow-ups till December 31, 2019 (Additional file 1: Fig. S1). T2D was diagnosed according to the ICD codes (Additional file 1: Table S1) with antidiabetic drug use and at least two outpatient visits or one hospitalization within one year for T2D. The algorithm for defining T2D using ICD codes was validated as 74.6% accurate [15]. Exclusion criteria were as follows: missing age or gender data, age below 18 or above 80 years, diagnosis of type 1 diabetes, hepatitis B virus infection, hepatitis C virus infection, alcohol-related disorders, dialysis, liver cirrhosis, esophageal varices with bleeding, ascites, hepatic encephalopathy, jaundice, hepatic failure, hepatocellular carcinoma (HCC), and liver transplant before the index date. The study also excluded patients who died or were lost to follow-up and diagnosed with HCC within 6 months of the index date to avoid latent morbidity or mortality.
We defined patients who had received GLP-1 RAs after T2D diagnosis as GLP-1 RA users and those who had never received GLP-1 RAs during the study period as nonusers. The first date of GLP-1 RA use was set as the index date of the study group. We recorded the index date for the control cases with the same time interval from T2D diagnosis to the index date of the study group. Since GLP-1 RAs were launched in Taiwan in 2011, the index dates for the study and control groups were recorded after 2011. Some clinically relevant variates assessed were as follows: age, sex, family income, obesity, smoking, hypertension, dyslipidemia, stroke, coronary artery disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD, diagnosed one year before the index date), and number of oral antidiabetic drugs, insulin, antihypertensive drugs, aspirin, statin, fibrates use (drug use one year prior to index date), and duration of diabetes. We also counted the scores of the Charlson Comorbidity Index (CCI) [16] and Diabetes Complications Severity Index (DCSI) [17] to evaluate the disease burden and diabetes complications in these patients.
The outcomes of interest
This study compared the use or no-use of GLP-1 RAs in the following outcomes: liver cirrhosis development [18], hepatic failure (coagulopathy, hepatic coma, with or without other organ failures) [19], hepatocellular carcinoma, major adverse cardiovascular events (MACE, a composite outcome of admitted stroke, coronary artery disease, and heart failure), liver-related death (death due to liver cirrhosis, decompensated cirrhosis, hepatic failure, and HCC), cardiovascular death, and all-cause mortality (the confirmation and cause of death were from the link with the National Death Registry). For the outcomes of interest, we followed up with the patients until the occurrence of outcomes, death, or the end of the study period on December 31, 2019, whichever appeared first.
Statistical analysis
We performed 1:1 propensity score matching to match and balance the variation in the study and control groups [20]. Non-parsimonious multivariable logistic regression was used to estimate the propensity score for every person who received GLP-1 RAs. The GLP-1 RA use was treated as a dependent variable, and 37 critical variables (including age, sex, income, obesity, smoking, comorbidities, medications and duration of diabetes) were used as independent variables (Table 1). We used greedy nearest-neighbor matching to perform optimal matching and matched the control group without replacement. The nearest-neighbor algorithm was used to identify matched pairs with a width of less than 0.001. We assumed a standardized mean difference (SMD) of less than 0.1 as a negligible difference between the study and control groups.
Crude and multivariate-adjusted Cox proportional hazards models were used to compare the endpoints between GLP-1 RA users and nonusers. We presented the results as hazard ratios (HR) and 95% confidence interval (CI). The Schoenfeld residuals and complementary log–log plots were used to check the proportional-hazards assumption. We used a stepwise approach to adjust for the variables in the Cox models, as follows: Model 1: adjusted for sex and age; Model 2: adjusted for sex, age, income, and obesity; Model 3: adjusted for sex, age, income, obesity, and comorbidities; Model 4: adjusted for sex, age, income, obesity comorbidities, medications and duration of diabetes as shown in Table 1. Kaplan–Meier method was used to describe the cumulative incidence of outcomes between GLP-1 RA use and no-use over the follow-up time. We performed the subgroup analysis, including the subgroups of sex, age, comorbidities, CCI, DCSI, and medications, of GLP-1 RA use versus no use in the outcomes of all-cause death, cardiovascular diseases, cardiovascular death, and liver-related death. We also performed dose–response analysis on the cumulative duration of < 182, 182–364, > 364 days of GLP-1 RA use versus no use in the outcomes of all-cause death, cardiovascular diseases, cardiovascular death, and liver-related death.
We considered the two-tailed p-value < 0.05 statistically significant and used SAS version 9.4 and Stata SE version 11.0 for analysis.
| Variables | Pre-matched patients | Pre-matched patients | SMD | Post-matched patients | Post-matched patients | SMD | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| without GLP-1 RA | with GLP-1 RA | without GLP-1 RA | with GLP-1 RA | |||||||
| (N= 1538,337) | (N= 31216) | (N= 31156) | (N= 31156) | |||||||
| n | % | n | % | n | % | n | % | |||
| Sex | ||||||||||
| female | 783862 | 50.96 | 16770 | 53.72 | 0.055 | 16664 | 53.49 | 16728 | 53.69 | 0.004 |
| male | 754475 | 49.04 | 14446 | 46.28 | 0.055 | 14492 | 46.51 | 14428 | 46.31 | 0.004 |
| Age | ||||||||||
| 18–40 | 127181 | 8.27 | 5783 | 18.53 | 0.305 | 5613 | 18.02 | 5744 | 18.44 | 0.011 |
| 41–60 | 667332 | 43.38 | 15557 | 49.84 | 0.13 | 15567 | 49.96 | 15536 | 49.87 | 0.002 |
| 61–80 | 743824 | 48.35 | 9876 | 31.64 | 0.346 | 9976 | 32.02 | 9876 | 31.7 | 0.007 |
| mean, (SD)a | 58.9 | 12.11 | 53.09 | 12.97 | 0.463 | 53.35 | 12.92 | 53.12 | 12.96 | 0.018 |
| Income, New Taiwan Dollars | ||||||||||
| < 22000 | 361136 | 23.48 | 6195 | 19.85 | 0.088 | 6151 | 19.74 | 6189 | 19.86 | 0.003 |
| 22000–44999 | 891505 | 57.95 | 18393 | 58.92 | 0.02 | 18399 | 59.05 | 18359 | 58.93 | 0.003 |
| > 44999 | 285,696 | 18.57 | 6628 | 21.23 | 0.067 | 6606 | 21.2 | 6608 | 21.21 | < 0.001 |
| Comorbidities | ||||||||||
| Obesity | 45042 | 2.93 | 3711 | 11.89 | 0.347 | 3492 | 11.21 | 3670 | 11.78 | 0.018 |
| Smoking | 41955 | 2.73 | 1348 | 4.32 | 0.086 | 1361 | 4.37 | 1344 | 4.31 | 0.003 |
| Hypertension | 976049 | 63.45 | 22009 | 70.51 | 0.15 | 22073 | 70.85 | 21970 | 70.52 | 0.007 |
| Dyslipidemia | 1,098,806 | 71.43 | 26660 | 85.4 | 0.345 | 26756 | 85.88 | 26602 | 85.38 | 0.014 |
| Stroke | 79714 | 5.18 | 1448 | 4.64 | 0.025 | 1465 | 4.7 | 1448 | 4.65 | 0.003 |
| Coronary artery disease | 272876 | 17.74 | 5204 | 16.67 | 0.028 | 5233 | 16.8 | 5200 | 16.69 | 0.003 |
| Heart failure | 53934 | 3.51 | 1225 | 3.92 | 0.022 | 1164 | 3.74 | 1222 | 3.92 | 0.01 |
| Chronic kidney disease | 199447 | 12.97 | 6414 | 20.55 | 0.204 | 6481 | 20.8 | 6398 | 20.54 | 0.007 |
| COPD | 364499 | 23.69 | 7649 | 24.5 | 0.019 | 7515 | 24.12 | 7627 | 24.48 | 0.008 |
| CCI | ||||||||||
| 1 | 1364298 | 88.69 | 25273 | 80.96 | 0.217 | 25128 | 80.65 | 25225 | 80.96 | 0.008 |
| 2–3 | 151095 | 9.82 | 4789 | 15.34 | 0.167 | 4842 | 15.54 | 4779 | 15.34 | 0.006 |
| > 3 | 22944 | 1.49 | 1154 | 3.7 | 0.139 | 1186 | 3.81 | 1152 | 3.7 | 0.006 |
| DCSI | ||||||||||
| 0 | 606665 | 39.44 | 6475 | 20.74 | 0.416 | 6436 | 20.66 | 6470 | 20.77 | 0.003 |
| 1 | 336418 | 21.87 | 6008 | 19.25 | 0.065 | 5921 | 19 | 6000 | 19.26 | 0.006 |
| ≥ 2 | 595254 | 38.69 | 18733 | 60.01 | 0.436 | 18799 | 60.34 | 18686 | 59.98 | 0.007 |
| Medication | ||||||||||
| Metformin | 993488 | 64.58 | 30488 | 97.67 | 0.933 | 30619 | 98.28 | 30428 | 97.66 | 0.043 |
| Sulfonylurea | 699012 | 45.44 | 27292 | 87.43 | 0.993 | 27390 | 87.91 | 27233 | 87.41 | 0.015 |
| Meglitinides | 114479 | 7.44 | 7562 | 24.22 | 0.472 | 7516 | 24.12 | 7537 | 24.19 | 0.002 |
| Thiazolidinedione | 210669 | 13.69 | 16148 | 51.73 | 0.887 | 16280 | 52.25 | 16103 | 51.69 | 0.011 |
| DPP-4 inhibitors | 337,587 | 21.94 | 25403 | 81.38 | 1.479 | 25880 | 83.07 | 25343 | 81.34 | 0.045 |
| SGLT2 inhibitors | 33373 | 2.17 | 7369 | 23.61 | 0.675 | 6736 | 21.62 | 7315 | 23.48 | 0.044 |
| Insulin | 247598 | 16.1 | 20628 | 66.08 | 1.18 | 20560 | 65.99 | 20568 | 66.02 | 0.001 |
| ACEI/ARB | 805284 | 52.35 | 21328 | 68.32 | 0.331 | 21318 | 68.42 | 21278 | 68.3 | 0.003 |
| β-blockers | 373613 | 24.29 | 6896 | 22.09 | 0.052 | 6820 | 21.89 | 6885 | 22.1 | 0.005 |
| Calcium-channel blockers | 797882 | 51.87 | 16515 | 52.91 | 0.021 | 16648 | 53.43 | 16492 | 52.93 | 0.01 |
| Diuretics | 447044 | 29.06 | 11302 | 36.21 | 0.153 | 11315 | 36.32 | 11281 | 36.21 | 0.002 |
| Statin | 838452 | 54.5 | 24265 | 77.73 | 0.506 | 24345 | 78.14 | 24211 | 77.71 | 0.01 |
| Fibrates | 337082 | 21.91 | 10790 | 34.57 | 0.284 | 10632 | 34.13 | 10766 | 34.56 | 0.009 |
| Aspirin | 460946 | 29.96 | 11425 | 36.6 | 0.141 | 11453 | 36.76 | 11409 | 36.62 | 0.003 |
| Number of oral antidiabetic drugs | ||||||||||
| 1 | 763995 | 49.66 | 1027 | 3.29 | 1.235 | 749 | 2.4 | 1027 | 3.3 | 0.054 |
| 2–3 | 547930 | 35.62 | 6658 | 21.33 | 0.321 | 6551 | 21.03 | 6658 | 21.37 | 0.008 |
| > 3 | 226412 | 14.72 | 23531 | 75.38 | 1.538 | 23856 | 76.57 | 23471 | 75.33 | 0.029 |
| Duration of diabetes, years | ||||||||||
| Mean, (SD) | 3.88 | 2.89 | 6.95 | 3.2 | 1.006 | 6.9 | 3.06 | 6.94 | 3.2 | 0.014 |
Results
From January 1, 2008, to December 31, 2018, we identified 3,432,732 newly diagnosed T2D patients from our NHIRD (Additional file: Fig. S1). We used a 1-to-1 propensity score matching method to find 31,183 pairs of GLP-1 RA nonusers and users. The total follow-up time for the study is 167,619 person-years. The median (Q1, Q3) follow-up time for GLP-1 RA users and nonusers were 2.19 (1.35, 3.52) and 2.14 (1.19, 3.68) years, respectively. 1
Clinically-related variables were all well-matched between the study and control groups (Table 1).
Among the matched cohorts of patients with T2D, 1093 (3.51%) GLP-1 RA nonusers and 480 (1.54%) users died during the follow-up period; the incidence rates of all-cause mortality were 13.06 and 5.67 per 1000 person-years, respectively (Table 2). The multivariable-adjusted models showed that GLP-1 RA use was associated with a significantly lower risk of all-cause mortality (Model 1,2,3,4 aHRs are 0.46,0.46,0.46,0.48) than no-use of GLP-1 RAs (Table 2). Compared with GLP-1 RA no-use, GLP-1 RA use was also associated with a significantly reduced risk of liver-related death (Model 1,2,3,4 aHRs are 0.36, 0.35, 0.35, 0.32), major adverse cardiovascular events (Model 1,2,3,4 aHRs are 0.92, 0.91, 0.92, 0.92), and cardiovascular death (Model 1,2,3,4 aHRs are 0.55, 0.54, 0.55, 0.57), but without significant difference in the risks of cirrhosis development (aHR 1.10, 95%CI 0.88–1.37), hepatic failure (aHR 0.92, 95%CI 0.66–1.30), and hepatocellular carcinoma (aHR 0.91, 95%CI 0.59–1.40).
The Kaplan–Meier method showed that GLP-1 RA use had a significantly lower risk in cumulative incidences of liver-related death (Log-rank test p = 0.004), all-cause death (Log-rank test p < 0.001; Fig. 1), cardiovascular events (Log-rank test p < 0.001), and cardiovascular death (Log-rank test, p < 0.001; Additional file 1: Fig. S2) than GLP-1 RA no-use.
Subgroup analysis of GLP-1 RA use vs. no-use in the risks of cardiovascular disease, cardiovascular mortality, and all-cause mortality showed that GLP-1 RA use was associated with a lower risk in the subgroups of gender, age, comorbidities, and drug use (Additional file 1: Table S2-S4). However, in the subgroups for obesity [aHR 1.08, 95%CI 0.85–1.35) and SGLT2 inhibitors use (aHR 1.05, 95%CI 0.82–1.35), GLP-1 RAs were associated with a non-significantly higher risk of cardiovascular disease (Additional file 1: Table S4). The potential reason for this could be that these two subgroups have smaller sample sizes, resulting in a lower incidence rate of cardiovascular events, which in turn leads to less stable statistical results. Compared with no-use of GLP-1 RAs, GLP-1 RA use had a significantly lower risk of liver-related death in the subgroups of sex (female, male, p < 0.05) and age (< 70, p = 0.0015) (Additional file 1: Table S5).
Compared to no use of GLP-1 RAs, the cumulative duration of < 182, 182–364, > 364 days of GLP-1 RA use showed a significantly reduced risk of all-cause death with a significant p-value for trend (p < 0.0001). Cumulative duration of 182–364, > 364 days of GLP-1 RA use exhibited a significantly lower risk of major adverse cardiovascular events and cardiovascular death with a with a significant p-value for trend (p < 0.0001) of cardiovascular death. A cumulative duration of ≧90 days of GLP-1 RA use showed a significantly lower risk of liver-related death with a significant p-value for trend (p = 0.0045; Table 3).
The cumulative incidences of liver-related death (), mortality () between GLP-1 RA users and nonusers a b
| Outcome | T2D patients without GLP-1 RA | T2D patients with GLP-1 RA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | PY | IR | n | PY | IR | cHR | aHR1 | aHR2 | aHR3 | aHR4 | (95% CI) | |
| All-cause mortality | 1093 | 83691 | 13.06 | 480 | 84680 | 5.67 | 0.43 | 0.46 | 0.46 | 0.46 | 0.48 | (0.43, 0.53)*** |
| MACE | 1653 | 80860 | 20.44 | 1486 | 82211 | 18.08 | 0.88 | 0.92 | 0.91 | 0.92 | 0.92 | (0.86, 0.99)* |
| Cardiovascular death | 197 | 83691 | 2.35 | 103 | 84680 | 1.22 | 0.52 | 0.55 | 0.54 | 0.55 | 0.57 | (0.45, 0.72)*** |
| Liver-related death | 22 | 83691 | 0.26 | 7 | 84680 | 0.08 | 0.31 | 0.36 | 0.35 | 0.35 | 0.32 | (0.13, 0.75)** |
| Liver cirrhosis | 155 | 83495 | 1.86 | 165 | 84421 | 1.95 | 1.05 | 1.08 | 1.08 | 1.08 | 1.1 | (0.88, 1.37) |
| Hepatic failure | 71 | 83603 | 0.85 | 63 | 84596 | 0.74 | 0.87 | 0.9 | 0.89 | 0.9 | 0.92 | (0.66, 1.30) |
| Hepatocellular carcinoma | 44 | 83685 | 0.53 | 41 | 84664 | 0.48 | 0.93 | 1.02 | 1 | 1.01 | 0.91 | (0.59, 1.40) |
| Variables | All-cause mortality | ||||||
| n | PY | IR | cHR | (95% CI) | aHR† | (95% CI) | |
| Non-use of GLP-1 RAs | 1093 | 83691 | 13.06 | 1 | (reference) | 1 | (reference) |
| Cumulative duration of GLP-1 RAs (days) | |||||||
| > 182 | 308 | 33875 | 9.09 | 0.74 | (0.65, 0.84)*** | 0.79 | (0.69, 0.90)*** |
| 182–364 | 101 | 21978 | 4.6 | 0.38 | (0.31, 0.46)*** | 0.44 | (0.36, 0.54)*** |
| > 364 | 71 | 28827 | 2.46 | 0.17 | (0.13, 0.21)*** | 0.19 | (0.15, 0.24)*** |
| P for trend | < 0.0001 | ||||||
| Liver-related death | |||||||
| Variables | n | PY | IR | cHR | (95% CI) | aHR† | (95% CI) |
| Non-use of GLP-1 RAs | 22 | 83691 | 0.26 | 1 | (reference) | 1 | (reference) |
| Cumulative duration of GLP-1 RAs (days) | |||||||
| < 90 | 3 | 20886 | 0.14 | 0.56 | (0.17, 1.88) | 0.5 | (0.15, 1.69) |
| ≧90 | 4 | 63794 | 0.06 | 0.23 | (0.08, 0.68)** | 0.25 | (0.09, 0.73)* |
| P for trend | 0.0045 | ||||||
| Variables | Cardiovascular mortality | ||||||
| n | PY | IR | cHR | (95% CI) | aHR† | (95% CI) | |
| Non-use of GLP-1 RAs | 197 | 83691 | 2.35 | 1 | (reference) | 1 | (reference) |
| Cumulative duration of GLP-1 RAs (days) | |||||||
| > 182 | 67 | 33875 | 1.98 | 0.9 | (0.68, 1.19) | 0.97 | (0.73, 1.28) |
| 182–364 | 24 | 21978 | 1.09 | 0.5 | (0.33, 0.76)** | 0.59 | (0.38, 0.90)* |
| > 364 | 12 | 28827 | 0.42 | 0.16 | (0.09, 0.28)*** | 0.17 | (0.09, 0.31)*** |
| P for trend | < 0.0001 | ||||||
| Variables | Cardiovascular events | ||||||
| n | PY | IR | cHR | (95% CI) | aHR† | (95% CI) | |
| Non-GLP-1 RA drug days | 1653 | 80860 | 20.44 | 1 | (reference) | 1 | (reference) |
| Cumulative duration of GLP-1 RAs (days) | |||||||
| > 182 | 710 | 32784 | 21.66 | 1.12 | (1.02, 1.22)* | 1.16 | (1.06, 1.26)** |
| 182–364 | 330 | 21484 | 15.36 | 0.77 | (0.69, 0.87)*** | 0.82 | (0.73, 0.93)** |
| > 364 | 446 | 27943 | 15.96 | 0.72 | (0.65, 0.80)*** | 0.75 | (0.68, 0.83)*** |
| P for trend | 0.6991 | ||||||
Discussion
This study showed that GLP-1 RA use was associated with a significantly lower risk of all-cause mortality, cardiovascular events, cardiovascular and liver-related mortality. However, there was no significant difference in the risk of cirrhosis development, hepatic failure, and hepatocellular carcinoma in patients with T2D and without viral hepatitis. Compared with the no-use of GLP-1 RAs, a longer cumulative duration of GLP-1RA use had a lower risk of liver-related and cardiovascular mortality, all-cause mortality, and cardiovascular events. Moreover, subgroups of age, gender, comorbidities, and medications showed reduced risks of cardiovascular events and cardiovascular and overall mortality from GLP-1RAs.
NAFLD is considered the most common cause of cryptogenic cirrhosis; however, there are no adequate preventive measures [21]. One meta-analysis showed that liraglutide could significantly improve alanine transaminase (ALT) levels more than placebo in patients with T2D [22]. A randomized controlled study on liraglutide in 52 persons with NASH (with or without T2D) showed that liraglutide had a significantly higher rate of NASH resolution and lower risk in the progression of liver fibrosis [11]. A randomized controlled trial of semaglutide in 320 persons with NASH (with or without T2D) showed that subcutaneous semaglutide led to a significantly higher proportion of persons with the resolution of NASH than the placebo group, with no statistically significant difference in the improvement of fibrosis stage [12]. The post hoc analysis of phase 2 of the tirzepatide trial showed that a higher dose of this novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist could significantly decrease the level of NASH-related biomarkers and increase adiponectin level in patients with T2D [23]. These studies suggest that GLP-1RAs may improve liver function and insulin sensitivity, reduce liver fat and hepatic inflammation, and increase the resolution of NASH; but about the mitigation of hepatic fibrosis and prevention of liver cirrhosis are unclear. Our study showed that GLP-1 RA use in patients with T2D without viral hepatitis exhibited no significant difference in preventing liver cirrhosis development compared to GLP-1 RA no-use.
Patients with NASH, especially those with fibrosis, constitute a high-risk group for HCC, and the number of HCCs caused by NAFLD is increasing [1, 24]. Furthermore, diabetes can increase the risk of liver cancers in patients with NAFLD [1, 4]. Large-scale randomized control trials have not shown an association between GLP-1 RAs and liver cancers [9]. Our large-scale study also showed no significant difference in the risk of incident HCC between GLP-1 RA use and no-use in patients with T2D.
GLP-1 RAs are not mainly eliminated by hepatic metabolism [9]. No clinical study has shown prominent hepatotoxicity with GLP-1 RA use [25]. Our study also showed no significant association between GLP-1 RA use and hepatic failure. However, it showed that GLP-1 RA use was associated with a lower risk of liver-related mortality. Simon et al. conducted a cohort study showing that GLP-1 RA use was associated with a lower risk of cirrhotic decompensation than DPP-4 inhibitors or sulfonylureas in patients with liver cirrhosis [26]. GLP-1 RA use might reduce the risk of hepatic complications or cirrhotic decompensation in our patients after enrolment and reduce the risk of liver-related death. However, because the incidence of liver-related death, hepatic failure, and hepatocellular carcinoma is low in this study, the results regarding liver-related death, hepatic failure, and hepatocellular carcinoma should be interpreted with extreme caution.
Cardiovascular disease is the major complication and cause of death in patients with T2D or NAFLD [1, 27]. In patients with NAFLD, higher inflammatory scores have a higher risk of cardiovascular disease [24, 27]. The cardiovascular outcome trials of GLP-1 RAs demonstrated that GLP-1 RAs could significantly reduce the risk of major adverse cardiovascular events and cardiovascular mortality in patients with T2D [9]. Our study also revealed that GLP-1 RA use was associated with a significantly lower risk of cardiovascular diseases and cardiovascular mortality than GLP-1 RA no-use in patients with T2D and without viral hepatitis. GLP-1 RAs may reduce the risk of cardiovascular morbidity and mortality by improving dyslipidemia, lowering blood pressure, and modifying the process of atherosclerosis [10, 27, 28].
Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis, has a higher liver-related and overall mortality risk than the general population [1, 3]. Randomized studies have shown that GLP-1 RAs could reduce the risk of all-cause mortality compared to a placebo in patients with T2D [28]. Our results also demonstrated that GLP-1 RA use was associated with a lower risk of all-cause mortality compared to no-use of GLP-1 RAs in patients with T2D and without viral hepatitis, which may be attributable to the reduced risks of cardiovascular events, and liver-related and cardiovascular mortality with GLP-1 RA use in this study.
This study has some disadvantages. First, the National Health Insurance database lacked details on smoking habits, diet, physical activity, and family history, which may have affected the results. We tried to balance the baseline characteristics of the study and control groups to increase their comparability. Second, this database lacked details on hemoglobin A1C, glucose, lipid indicators (TC, TG, LDL-c, HDL-c), liver function (ALT, AST), kidney function (CCr, Bun), cardiac function (TnT), imaging, and histopathology results. This limitation prevented us from evaluating the diabetes status and accurately diagnosing and staging NAFLD, NASH, liver fibrosis, and cirrhosis. We used the CCI, DCSI scores, insulin, and the number of oral antidiabetic drugs to evaluate T2D severity. We used the diagnosis of T2D and excluded patients with hepatitis B, hepatitis C infection, and alcohol-related disorders to create a representative cohort of patients with T2D and NAFLD. Third, the participants in this study were mainly of Chinese ethnicity. Therefore, the results may not apply to other ethnic groups. However, our results may provide some important information about the Oriental population. Finally, a cohort study is usually subject to unknown or unobserved confounding factors; therefore, randomized controlled trials are recommended to confirm our results.
Conclusions
Our research showed that GLP-1 RAs could not prevent the development of liver cirrhosis. However, it could reduce the risks of cardiovascular disease, cardiovascular, and overall mortality in patients with type 2 diabetes without viral hepatitis among Taiwan population. GLP-1 RAs may be suitable for patients with type 2 diabetes coexisting with NAFLD. However, more prospective studies and randomized controlled trials are warranted to verify the findings.
Supplementary Information
Acknowledgements
We are grateful to Health Data Science Center, China Medical University Hospital, for providing administrative, technical, and funding support. The funders had no role in study design, data collection, data analysis, the decision to publish, or manuscript preparation. No additional external funding was received for this study.
Abbreviations
Authors’ contributions
FSY, MCH, and CMH engaged in study concept and design; YHS, JCCW, and CCH engaged in the acquisition of data; FSY, MCH, and CMH engaged in the statistical analysis and interpretation of results; FSY, JCCW, and CCH engaged in the drafting of the manuscript; MCH, YHS, and CMH engaged in the critical revision of the manuscript for important intellectual content. YHS, CCH, and CMH engaged in obtaining funds. MCH, JCCW, YHS, and CCH engaged in administrative, technical, or material support. CCH and CMH engaged in study supervision. All authors read and approved the final manuscript.
Authors’ Twitter handles
@ChihChengHsu1(Chih-Cheng Hsu) and @yenfushun1(Fu-Shun Yen).
Funding
This study is supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW109-TDU-B-212–114004), China Medical University Hospital (DMR-111–105). This work also received grants from the Taipei Veterans General Hospital (V105C-204, V110C-175) and the Ministry of Science and Technology, R.O.C (MOST 110–2314-B-075–027-MY3).
Availability of data and materials
Data of this study are available from the National Health Insurance Research Database (NHIRD) published by Taiwan National Health Insurance (NHI) Administration. The data utilized in this study cannot be made available in the paper, the supplemental files, or in a public repository due to the ‘‘Personal Information Protection Act’’ executed by Taiwan government starting from 2012. Requests for data can be sent as a formal proposal to the NHIRD Office (https://dep.mohw.gov.tw/DOS/cp-2516-3591-113.html↗) or by email to stsung@mohw.gov.tw.
Declarations
Ethics approval and consent to participate
All patient and health care information was encrypted before release to protect the privacy of individuals. The Research Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115-CR4) approved this study and waived informed consent from patients.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Contributor Information
Chii-Min Hwu, Email: chhwu@vghtpe.gov.tw.
Chih-Cheng Hsu, Email: cch@nhri.edu.tw.
References
Associated Data
Supplementary Materials
Data Availability Statement
Data of this study are available from the National Health Insurance Research Database (NHIRD) published by Taiwan National Health Insurance (NHI) Administration. The data utilized in this study cannot be made available in the paper, the supplemental files, or in a public repository due to the ‘‘Personal Information Protection Act’’ executed by Taiwan government starting from 2012. Requests for data can be sent as a formal proposal to the NHIRD Office (https://dep.mohw.gov.tw/DOS/cp-2516-3591-113.html↗) or by email to stsung@mohw.gov.tw.